Loading
Every dated change on the records linked to NPM1-mutated and KMT2A-rearranged acute myeloid leukaemia, newest first: approvals and regulatory steps on its medicines, trials that reported, guideline versions, milestones, and when this page itself was checked. Dates come from the records; none is inferred. Orientation, not medical advice.
Relapsed/refractory NPM1-mutated AML with no satisfactory alternative
CR 23%, ORR 33%, median OS 6.
A milestone in how this cancer is treated.